IPO News | Harmonicare Medical Holdings Files Listing Application with Hong Kong Stock Exchange

According to the Wise Finance app, the Hong Kong Stock Exchange disclosed on December 1st that GanZhou HeMei Pharmaceutical Co., Ltd. (referred to as HeMei Pharmaceutical) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with Guotou Securities International as its exclusive sponsor. The prospectus shows that HeMei Pharmaceutical was established in 2002 and is a biopharmaceutical company dedicated to discovering and developing proprietary small molecule drugs for autoimmune diseases and tumors. As of the last practicable date, the company's pipeline products include seven small molecule drug candidates (including two core products, Mufemilast and Hemay022). Mufemilast has already obtained NDA approval in China.